Abstract
The goal of acute stroke therapy is to salvage brain tissue by rapid cerebral artery recanalization to improve microcirculation. A major drawback of fibrinolysis is the activation of platelets leading to a high rate of re-occlusion. Antagonists of the platelet GPIIb/IIIa-receptor inhibit the binding of fibrinogen to platelets counteracting secondary thrombus formation. Also, they were shown to suppress thrombembolus formation and to limit lesion development in cerebral ischemia. We review the literature concerning the use of intravenously administered GPIIb/IIIa-receptor antagonists abciximab, eptifibatide and tirofiban for the treatment of patients with acute ischemic brain infarction. In multicenter, prospective, randomized and placebo-controlled trials abciximab had a higher cerebral bleeding risk, while tirofiban did not increase hemorrhage. When combined with fibrinolysis, abciximab and tirofiban were found to improve cerebral artery recanalization and tissue reperfusion resulting in reduced infarct volumes and improved neurological outcome. Thus, GPIIb/IIIareceptor antagonists have a great potential for the treatment of acute stroke.
Keywords: Stroke, fibrinolysis, reperfusion, hemorrhage, receptor polymorphism
Current Vascular Pharmacology
Title: Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease
Volume: 6 Issue: 1
Author(s): Rudiger J. Seitz and Mario Siebler
Affiliation:
Keywords: Stroke, fibrinolysis, reperfusion, hemorrhage, receptor polymorphism
Abstract: The goal of acute stroke therapy is to salvage brain tissue by rapid cerebral artery recanalization to improve microcirculation. A major drawback of fibrinolysis is the activation of platelets leading to a high rate of re-occlusion. Antagonists of the platelet GPIIb/IIIa-receptor inhibit the binding of fibrinogen to platelets counteracting secondary thrombus formation. Also, they were shown to suppress thrombembolus formation and to limit lesion development in cerebral ischemia. We review the literature concerning the use of intravenously administered GPIIb/IIIa-receptor antagonists abciximab, eptifibatide and tirofiban for the treatment of patients with acute ischemic brain infarction. In multicenter, prospective, randomized and placebo-controlled trials abciximab had a higher cerebral bleeding risk, while tirofiban did not increase hemorrhage. When combined with fibrinolysis, abciximab and tirofiban were found to improve cerebral artery recanalization and tissue reperfusion resulting in reduced infarct volumes and improved neurological outcome. Thus, GPIIb/IIIareceptor antagonists have a great potential for the treatment of acute stroke.
Export Options
About this article
Cite this article as:
Seitz J. Rudiger and Siebler Mario, Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease, Current Vascular Pharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157016108783331303
DOI https://dx.doi.org/10.2174/157016108783331303 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics A Review of the Primer Approximation Multiplex PCR (PAMP) Technique for Detecting Large Scale Cancer Genomic Lesions
Current Bioinformatics Nanoparticulate Carrier Mediated Intranasal Delivery of Insulin for the Restoration of Memory Signaling in Alzheimer’s Disease
Current Nanoscience Quassinoids: From Traditional Drugs to New Cancer Therapeutics
Current Medicinal Chemistry Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Targeting Epithelial-Mesenchymal Transition Phenotype for Gastro-Intestinal Cancer
Current Pharmaceutical Design The New Patient and Responsible Self-Medication Practices: A Critical Review
Current Drug Safety Editorial [Hot topic: An Overview on the Design, Development, Characterization and Applications of Novel Nanomedicines for Brain Targeting (Guest Editor: Eliana B. Souto)]
Current Nanoscience Network Theory to Understand Microarray Studies of Complex Diseases
Current Molecular Medicine Osteogenic Differentiation of Orofacial Tissue-Derived Mesenchymal Stem Cells- A Review
Current Tissue Engineering (Discontinued) Mechanisms of Action of Antiepileptic Drugs
Current Topics in Medicinal Chemistry Neurochemical and Neuropharmacological Aspects of Circadian Disruptions: An Introduction to Asynchronization
Current Neuropharmacology Applications of Genome Editing Tools in Stem Cells Towards Regenerative Medicine: An Update
Current Stem Cell Research & Therapy Early Life Programming of Obesity: The Impact of the Perinatal Environment on the Development of Obesity and Metabolic Dysfunction in the Offspring.
Current Diabetes Reviews Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics Brain Neuronal Nicotinic Receptors as New Targets for Drug Discovery
Current Pharmaceutical Design The Effects of Mesenchymal Stem Cells in Craniofacial Tissue Engineering
Current Stem Cell Research & Therapy